KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis

Stopped Sponsor decision due to slow enrollment and strategic consideration; not driven by any safety concerns.

Conditions

• System; Sclerosis
• Diffuse Cutaneous Systemic Sclerosis

Interventions

• DRUG: Belumosudil (KD025)
• DRUG: Placebo

Sponsor

Kadmon, a Sanofi Company